Thymus Messages Interferon Donations Contact Us Complete Alternative Medicine Solution Pharmacy Hepatitis C PharmacyLloyd's HCV Book Chapters

On The Radio

Background

Book Reviews

Order Book

Herb Schedule

Fax
Order Form

Read About:
NatCell Thymus
NatCell Liver
NatCell TLM
NatCell Mesenchyme
Aloe Vera
Milk Thistle
Reishi
Vitamin C
Lipoic Acid
Licorice Root
Cats Claw
Alfalfa
Dandelion Root
Olive Leaf
NADH
Eurocel
Lipotrope

Status:
Non-Profit

Shop Now

 

Coriolus Versicolor PSP clinical results,CANCER
August 8, 2003


Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer.

Tsang KW, Lam CL, Yan C, Mak JC, Ooi GC, Ho JC, Lam B, Man R, Sham JS, Lam WK.

Department of Medicine, The University of Hong Kong,
Queen Mary Hospital, Pokfulam, Hong Kong SAR, China.
kwttsang@hku.hk

BACKGROUND: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, and over 60% of patients present with advanced stages. Although polysaccharide peptides (PSP), isolated from the fungus Coriolus versicolor, have been reported to have anti-tumor effects, its clinical efficacy has not been properly evaluated.

METHODS: Double-blind placebo-controlled randomized study to evaluate the effects of 28-day administration of PSP (Windsor Pharmaceutical, Hong Kong) on patients, who had completed conventional treatment for advanced NSCLC.

RESULTS: Thirty-four patients, with no significant difference in their baseline demographic, clinical or tumor characteristics, or previous treatment regimes (P>0.05) were recruited into each of the PSP and control arms. After 28-day treatment, there was a significant improvement in blood leukocyte and neutrophil counts, serum IgG and IgM, and percent of body fat among the PSP, but not the control, patients (P<0.05). Although the evaluable PSP patients did not improve in NSCLC-related symptoms, there were significantly less PSP patients withdrawn due to disease progression, than their control counterparts (5.9 and 23.5%, respectively; P=0.04; OR 4.00). There was no reported adverse reaction attributable to the trial medications.

CONCLUSION: PSP treatment appears to be associated with slower deterioration in patients with advanced NSCLC.

Publication Types:
· Clinical Trial
· Clinical Trial, Phase II
· Randomized Controlled Trial

Diane Bilodeau, PhD
Chargée de projets/ Project Manager
Affaires scientifiques/ Scientific Affairs

Atrium Biotechnologies PSP Now available in the Pharmcacy
 PSP Classic            PSP-II 


Return to Articles
 

Hep C Pharmacy | Cancer Pharmacy | Order Book | Awards | Thymus | Search This Site

  These statements are not intended to promote, sell, advertise
or otherwise induce anyone to purchase any product on this web site.

These statements have NOT been evaluated by the FDA
and are for informational purposes only.
 

All ©2001 Lloyd Wright
site maintained by FluxRostrum